Douglas C. Lane & Associates’s Pfizer PFE Stock Holding History

Douglas C. Lane & Associates’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$2.92M	Sell	95,240 -6,382	-6%	-$201K	0.08%	133
2015 Q3	$3.03M	Buy	101,622 +5,390	+6%	+$173K	0.09%	131
2015 Q2	$3.06M	Buy	96,232 +5,667	+6%	+$185K	0.08%	133
2015 Q1	$2.99M	Buy	90,565 +2,726	+3%	+$86.7K	0.08%	130
2014 Q4	$2.6M	Buy	87,839 +1,705	+2%	+$48.9K	0.07%	129
2014 Q3	$2.42M	Buy	86,134 +7,227	+9%	+$203K	0.07%	127
2014 Q2	$2.22M	Buy	78,907 +24	+0%	+$684	0.07%	130
2014 Q1	$2.4M	Buy	78,883 +10,684	+16%	+$319K	0.08%	122
2013 Q4	$1.98M	Buy	68,199 +3,157	+5%	+$91.9K	0.07%	125
2013 Q3	$1.77M	Buy	65,042 +4,185	+7%	+$114K	0.06%	126
2013 Q2	$1.62M	Buy	+60,857	New	+$1.68M	0.06%	128

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Douglas C. Lane & Associates's PFE Position: Q4 2015 in Review

Douglas C. Lane & Associates reduced its Pfizer (PFE) stake by 6.3% in Q4 2015, selling an estimated $201K and leaving 95,240 shares worth $2.92M. The position accounts for 0.08% of the portfolio, ranked #133.

Douglas C. Lane & Associates first reported a position in PFE in Q2 2013 and has held it in 11 quarters since. The position peaked at $3.06M in Q2 2015. 1,970 funds tracked by Wall St. Rank hold PFE as of Q4 2015.

Douglas C. Lane & Associates held 95,240 shares of Pfizer worth $2.92M as of Q4 2015.
Douglas C. Lane & Associates sold 6,382 Pfizer shares in Q4 2015, an estimated $201K.
Pfizer made up 0.08% of Douglas C. Lane & Associates's portfolio in Q4 2015, its #133 holding.
Douglas C. Lane & Associates first reported a position in Pfizer in Q2 2013 and has held it in 11 quarters since.
Douglas C. Lane & Associates's Pfizer position peaked at $3.06M in Q2 2015.
1,970 funds tracked by Wall St. Rank held Pfizer as of Q4 2015.

Based on Douglas C. Lane & Associates's 13F filing for Q4 2015, filed 25 Jan 2016.